July 25, 2016
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion of the stomach contents after every meal.

The AspireAssist device should not be used on patients with "...




Patients must be informed that Suprenza is a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended [see INDICATIONS AND USAGE and WARNINGS AND PRECAUTIONS].

Patients must be instructed on how much Suprenza to take, and when and how to take it [see DOSAGE AND ADMINISTRATION].

Advise pregnant women and nursing mothers not to use Suprenza (see Use In Specific Populations].

Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:

See also, for example, ADVERSE REACTIONS and Use in Specific Populations.

The patients must also be informed about

Tell patients to keep Suprenza in a safe place to prevent theft, accidental overdose, misuse or abuse. Selling or giving away Suprenza may harm others and is against the law.

Last reviewed on RxList: 7/2/2013
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.